Product Description

Etoposide hinders DNA repair, inhibits DNA replication, and induces cell death (apoptosis and autophagy) along with cell cycle arrest by reversibly inhibiting topoisomerase II. This reversible nature of its action suggests that prolonged administration may enhance its anti-tumor efficacy.

Screeningbio‘s K562/ Etoposide resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Etoposide is a topoisomerase II inhibitor widely used in the treatment of small cell lung cancer, testicular cancer, lymphomas, and various pediatric malignancies. It induces DNA strand breaks by stabilizing the topoisomerase II-DNA cleavable complex, leading to DNA damage, cell cycle arrest predominantly in the G2/M phase, and apoptosis in rapidly dividing cancer cells. Despite its clinical efficacy, acquired drug resistance significantly limits long-term treatment success.

The mechanisms underlying etoposide resistance involve multiple cellular alterations. Reduced expression or mutations in topoisomerase II isoforms (e.g., TOP2A/TOP2B) decrease drug target availability and binding affinity. Increased activity of ATP-binding cassette (ABC) transporters such as P-glycoprotein (MDR1/ABCB1) and ABCG2 enhances drug efflux and lowers intracellular accumulation. Enhanced DNA repair capacity—particularly through the activation of homologous recombination (HR) and non-homologous end joining (NHEJ) pathways—allows cancer cells to survive etoposide-induced DNA damage. Furthermore, upregulation of anti-apoptotic Bcl-2 family proteins, activation of PI3K/Akt and NF-κB survival signaling, and induction of autophagy or epithelial–mesenchymal transition (EMT) contribute to reduced drug sensitivity.

Understanding these resistance mechanisms is essential for developing effective therapeutic strategies. Potential approaches include combining etoposide with ABC transporter inhibitors, suppressing DNA repair machineries (e.g., using PARP inhibitors in HR-proficient tumors), targeting compensatory survival pathways, or employing patient-derived resistant cell models to guide personalized combination therapy.